Author | Charles A. Schiffer, MD


Which TKI Should Be Recommended as Initial Treatment for CML in Chronic Phase?

October 12, 2012

Resistance due to new mutations in the genes coding for the targeted proteins, as well as to changes in other signaling pathways, often develops, and newer drugs and perhaps combination approaches may be needed.

Second-Generation TKIs in Chronic Myelogenous Leukemia

April 15, 2008

Chronic myelogeneous leukemia (CML) is a biologically unique neoplasm resulting from a mutation producing a single abnormal protein that induces unregulated proliferation of myelopoiesis. Imatinib mesylate (Gleevec) profoundly inhibits the chimeric bcr/abl tyrosine kinase, and has dramatically improved the outlook for patients with CML in chronic phase.